AC
TNGX icon

Aristides Capital’s Tango Therapeutics TNGX Stock Holding History

Aristides Capital’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-64,300
Closed -$199K – 337
2024
Q4 		$199K Buy
+64,300
New +$299K 0.04% 245

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Aristides Capital's TNGX Position: Q1 2025 in Review

Aristides Capital sold out of Tango Therapeutics (TNGX) in Q1 2025, closing a stake of 64,300 shares — an estimated $199K sold.

Aristides Capital first reported a position in TNGX in Q4 2024 and held it in 1 quarter. The position peaked at $199K in Q4 2024. 122 funds tracked by Wall St. Rank hold TNGX as of Q1 2025.

  • Aristides Capital reported no remaining Tango Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Aristides Capital sold 64,300 Tango Therapeutics shares in Q1 2025, an estimated $199K.
  • Aristides Capital first reported a position in Tango Therapeutics in Q4 2024 and held it in 1 quarter.
  • Aristides Capital's Tango Therapeutics position peaked at $199K in Q4 2024.
  • 122 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2025.

Based on Aristides Capital's 13F filing for Q1 2025, filed 14 May 2025.